London, United Kingdom
Elaitra is a health care startup based in the United Kingdom, founded in 2018. This innovative company is focused on improving breast cancer detection through the use of state-of-the-art neural networks. Their AI technology, ViewFinder, which is FDA-cleared, enhances the interpretation of 3D X-Rays (Tomos) by radiologists, enabling them to read faster, more accurately, and with greater confidence.
What sets Elaitra apart is their impressive track record, as their technology outperformed Google Health / DeepMind with 55% fewer errors as published in Nature in 2020. Moreover, they achieved the highest single-model performances in the DREAMS Digital Mammography $1 million Challenge, which had 1,200 entrants worldwide.
Elaitra has been making significant strides through collaborations with industry leaders like NVIDIA and IBM, and working with the USA and UK's leading DBT clinicians. Furthermore, they are proud founder members of the London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, which was established as part of the UK Government’s Industrial Strategy Challenge Fund.
Recently, Elaitra secured a £600.00KPre Seed Round investment on 30 June 2023 from SFC Capital and Cancer Research Horizons, showcasing the confidence of the investment community in the company's potential and impact in the healthcare industry. With such promising developments and robust support, Elaitra is positioned to continue driving positive change in breast cancer detection and treatment.
